MiroBio
ExitedMiroBio, a spin-off from the University of Oxford, is a clinical-stage private biotechnology company focused on developing therapeutic agents and checkpoint agonist antibodies to restore immune balance in autoimmune patients.
MiroBio is tracked in the Tech.eu funding database. Based in Oxford, UK; active in Healthtech. Acquired by Gilead Sciences in 2022. Data as of Nov 2026.
Oxford, UKwww.mirobio.com ↗
Total raised
—
no tracked rounds
Funding rounds
0
Investors
0
distinct backers
Active since
—
Funding rounds
0 roundsNo funding rounds recorded.
Exit
Type
acquisition
Date
Aug 2022
Value
€396M
Acquiror
Gilead Sciences (United States of America)
Related news
Similar companies
same sector, similar size- Clinithink—UK · Healthtech
- Chiron Health AI—UK · Healthtech
- Ascentys—UK · Healthtech
- Stent Tek—UK · Healthtech
- MYndspan—UK · Healthtech
- Neoss—UK · Healthtech
Global coverage: FundingData